drugset
drugset / Trial / NCT03760575

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

NCT03760575 ↗

Phase 1 Recruiting 20 enrolled Abramson Cancer Center at Penn Medicine
NaSingle-groupOpen-labelTreatment

Summary

The study is a single-arm phase I trial to evaluate the safety, feasibility, and preliminary efficacy of the addition of pembrolizumab and image-guided resection to surgical therapy and chemotherapy for malignant pleural mesothelioma (MPM).

Timeline

Start
2023-01-10
Primary completion
2027-02-01
Completion
2027-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous
Background Cisplatin Other / unclassified 75 mg/m2 Intravenous
Background Pemetrexed Small molecule 500 mg/m2 Intravenous

Indications

malignant pleural mesothelioma